E. Schroeder

发表

Effect of levothyroxine administration on intestinal P‐glycoprotein expression: Consequences for drug disposition *

H. Kroemer, I. Cascorbi, A. Paneitz, 2002, Clinical pharmacology and therapeutics.

The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease.

H. Kroemer, I. Cascorbi, L. Walker, 2004, Current Alzheimer research.

Neurofilament expression in the rat brain after cerebral infarction: effect of age

C. Kessler, A. Popa-Wagner, S. Vogelgesang, 2003, Neurobiology of Aging.

Expression of Multidrug Resistance Proteins in Rat and Human Chronic Pancreatitis

U. Adam, B. Sperker, C. Kunert-Keil, 2004, Pancreas.

The effects of the human MDR1 genotype on the expression of duodenal P‐glycoprotein and disposition of the probe drug talinolol

Werner Siegmund, Eike Schroeder, H. Kroemer, 2002, Clinical pharmacology and therapeutics.

Carbamazepine regulates intestinal P‐glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans

Michael Zschiesche, Markus Grube, Christiane Modess, 2004, Clinical pharmacology and therapeutics.

Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans.

Christiane Kunert-Keil, Werner Siegmund, Eike Schroeder, 2002, Pharmacogenetics.

Activated microglia do not mediate the early deposition of Abeta in carriers of the apolipoprotein Eepsilon4 allele.

L. Walker, J. Pahnke, R. Warzok, 2002, Clinical neuropathology.

Cerebral β-amyloid deposition is augmented by the –491AA promoter polymorphism in non-demented elderly individuals bearing the apolipoprotein E ε4 allele

L. Walker, J. Pahnke, R. Warzok, 2002, Acta Neuropathologica.

Cerebral beta-amyloid deposition is augmented by the -491AA promoter polymorphism in non-demented elderly individuals bearing the apolipoprotein E epsilon4 allele.

L. Walker, J. Pahnke, R. Warzok, 2003, Acta neuropathologica.